Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8201a QT/PK study in HER2-expressing breast cancer
NCT03366428Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Change in QT Interval Corrected by Fridericia's Formula at Cycle 3, Maximum Serum Concentration at Cycle 3 and 1 more. Started Dec 2017; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03366428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366428.